Rubicon Research IPO

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated formulations. As of June 30, 2025, Rubicon Research had a portfolio of 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products approved by the US FDA. The company’s portfolio includes 66 commercialized products, with a US generic pharmaceutical market size of USD 2,455.7 million, of which Rubicon Research Limited contributed USD 195 million in Fiscal 2024. As of June 30, 2025, the company has 17 new products awaiting US FDA ANDA approval and 63 products at various stages of development. As of June 30, 2025, the company marketed over 350 SKUs to 96 customers, including three major wholesalers who, account for more than 90% of wholesale drug distribution in the US. The company also supplies group purchasing organizations (GPOs), national pharmacy chains, regional pharmacy chains, and managed care organizations. Beyond the US market, Rubicon Research Limited, directly or through third-party distribution partners, has registered or filed 48 product applications across Australia, the United Kingdom, Singapore, Saudi Arabia, and the United Arab Emirates and expects to commence commercial activities upon approval. The company also provides contract manufacturing services to select customers in India, Australia, and New Zealand. Rubicon Research Limited operates three manufacturing facilities in India and two US FDA inspected R&D facilities-one each in India and Canada. Competitive strengths Fastest-growing Indian pharmaceutical company amongst peers. Data-driven product selection framework Strong R&D capabilities Robust sales and distribution capabilities in the US Strong track record of compliance combined with expertise in cost effective manufacturing Experienced and entrepreneurial management team

The Company Rubicon Research IPO proposes to utilise the Net Proceeds from the Issue towards the following objects: S.No. Objects of the Issue Expected Amount (in Millions) 1 Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company 3,100 2 Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes

All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application. No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever Please read all Tearms and conditions , and agree to use the App